{"url_path":"/sec/fdmt/8-k/2026-07-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-20","source_url":"https://www.sec.gov/Archives/edgar/data/1650648/0001193125-26-308409-index.html","accession_number":"0001193125-26-308409","cik":"0001650648","ticker":"FDMT","issuer_name":"4D Molecular Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1650648/0001193125-26-308409-index.html","primary_entity_key":"0001650648","primary_entity_name":"4D Molecular Therapeutics, Inc."},"word_count":614,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn July 18, 2026, 4D Molecular Therapeutics, Inc. (the “Company”) reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating 4D-150 in a broad wet age-related macular degeneration (“wet AMD”) population.\n\n2-Year Data from PRISM Phase 2b Clinical Trial (Data Cutoff May 18, 2026):\n\nTrial and Patient Cohort Overview\n\n \n\n \n•\n \n\nThe Phase 2b trial enrolled 45 patients at two dose levels of a single intravitreal dose of 4D-150 (3E10 and 1E10 vg/eye); 3E10 vg/eye was chosen as the dose for the 4FRONT Phase 3 clinical trials\n\n \n\n \n•\n \n\nThe Phase 2b overall cohort enrolled patients with broad disease activity (n=30 dosed with 3E10 vg/eye and n=15 dosed with 1E10 vg/eye)\n\n \n\n \n•\n \n\nThe Phase 2b cohort subgroup comprised recently diagnosed patients (diagnosed within 6 months, n=15 at 3E10 vg/eye), which is most comparable to the population enrolled in the 4FRONT Phase 3 clinical trials\n\nPhase 2b Efficacy Results Through 2 Years:\n\n \n\n \n•\n \n\nConsistent maintenance of best corrected visual acuity (“BCVA”)\n\n \n\n \n•\n \n\nConsistent control of central subfield thickness (“CST”) as measured by optical coherence tomography\n\n \n\n \n•\n \n\nConsistent, durable and clinically meaningful reduction in treatment burden:\n\n \n\n \n•\n \n\nOverall cohort:\n\n \n\n \n•\n \n\n78% overall treatment burden reduction (2.7 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)\n\n \n\n \n•\n \n\nRecently diagnosed subgroup:\n\n \n\n \n•\n \n\n87% overall treatment burden reduction (1.6 mean supplemental injections per patient vs. 12.0 injections projected with on-label aflibercept 2 mg Q8W)\n\n \n\n \n•\n \n\nDose response maintained throughout 2 years in favor of the Phase 3 dose\n\nSafety Data for Phase 3 Dose in Overall PRISM Phase 1/2a & 2b Clinical Trial (n=71)\n\n \n\n \n•\n \n\n4D-150 continues to be well tolerated:\n\n \n\n \n•\n \n\nIntraocular inflammation:\n\n \n\n \n•\n \n\nAs previously reported, within approximately the first 6 months (28 weeks) post-4D-150 dosing, 2.8% (2 of 71) of patients had 4D-150-related 1+ (mild) intraocular inflammation (“IOI”) (SUN/NEI scales), which were transient 1+ vitreous cells noted at a single timepoint\n\n \n\n \n•\n \n\nFollowing the first 28 weeks post-4D-150 dosing, no new cases of inflammation with 2 to more than 4 years of follow-up on all patients as of the data cutoff\n\n \n\n \n•\n \n\nNo 4D-150-related hypotony, endophthalmitis, vasculitis, occlusive/non-occlusive retinal vasculitis or choroidal effusions observed to date\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and expressed statements regarding the therapeutic potential, treatment-burden reduction, durability, and success of clinical trials for 4D-150. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “anticipate,” “intend,” “project,” “continue,” “target” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks and uncertainties that are described in greater detail in the section entitled “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q filed on May 7, 2026, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics’ current views and should not be relied upon as representing its views as of any subsequent time. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n4D MOLECULAR THERAPEUTICS, INC.\n\nDate: July 20, 2026\n \n\n \nBy:\n \n\n/s/ Kristian Humer\n\n \n\n \n\n \n\nKristian Humer\n\nChief Financial Officer"}